"Our half year results reflect continued strong momentum, with growth across all three therapeutic areas, particularly in our rare liver disease franchise, which is expanding rapidly and progressing well," said David Loew, Chief Executive Officer, Ipsen. "Building on that performance, I am pleased to increase our full year guidance in terms of sales and profitability." "I'm also delighted to report robust progression in our pipeline and portfolio, including the recent European Commission approval of Cabomet ...

Core Insights - Ipsen reported strong sales growth for Q1 2025, with total sales reaching €918.8 million, reflecting an increase of 11.7% as reported and 11.6% at constant exchange rates (CER) [2][7] - The company highlighted significant growth in its Rare Disease segment, which saw a remarkable increase of 78.4% in sales, driven by innovative medicines [2][7] - Ipsen confirmed its full-year financial guidance for 2025, acknowledging potential negative impacts on Somatuline sales due to increased generic competition [3][7] Sales Performance - Oncology sales amounted to €655.0 million, up 8.5% [2] - Neuroscience sales reached €193.5 million, reflecting an 8.0% increase [2] - Rare Disease sales were €70.3 million, marking a substantial growth of 78.4% [2] Strategic Initiatives - The CEO emphasized the ongoing transformation of the company and the importance of 2025 for Ipsen, with multiple product launches and milestones expected [2] - Ipsen is advancing its pipeline with the regulatory filing for tovorafenib accepted by EMA for pediatric low-grade glioma, indicating a commitment to innovation in challenging cancer treatments [4][5] Financial Guidance - Ipsen confirmed its financial guidance for 2025, which includes anticipated challenges from generic competition affecting Somatuline sales [3] - The company expects total sales growth to exceed 5.0% at constant currency, with a core operating margin greater than 30.0% [8] Upcoming Milestones - Key milestones anticipated in 2025 include regulatory decisions for Cabometyx and fidrisertib, as well as proof-of-concept data for LANT [9] - The company initiated Phase I trials for IPN01195, a RAF inhibitor, complementing its existing pipeline [5] Refinancing Activities - Ipsen successfully completed its inaugural Rated Public Bond of €500 million with a coupon of 3.875%, which is part of its refinancing strategy [10]